Were,At the cap raising Progen had about the middle of last year...

Were,
At the cap raising Progen had about the middle of last year the question was asked re one license to one company for all cancer types. Not the case. The answer given was that they would be able to issue multiple license's to either one company or several companies and the licence would be type specific ie for lung or myeloma or melanoma. You will have noticed the language they have been using recently where they talk about completeness of the data set relating to multiple cancer types. Sounds like they want to keep their options open plus embracing the maximun flexibility. Augers well in my opinion for a very good outcome.